D. Boral Capital Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital's price objective points to a potential upside of 145.94% from the stock's current price.

URGN has been the topic of a number of other reports. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Oppenheimer restated an "outperform" rating and issued a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, UroGen Pharma presently has an average rating of "Buy" and a consensus target price of $43.70.

UroGen Pharma Trading Up 1.1 %

NASDAQ:URGN traded up $0.12 during mid-day trading on Thursday, hitting $10.17. 108,509 shares of the stock traded hands, compared to its average volume of 416,969. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a market capitalization of $238.37 million, a price-to-earnings ratio of -3.22 and a beta of 1.09. UroGen Pharma has a 52 week low of $9.78 and a 52 week high of $20.70. The firm's 50 day moving average is $11.25 and its two-hundred day moving average is $13.01.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analysts' expectations of $24.22 million. During the same quarter in the previous year, the company posted ($0.68) earnings per share. On average, equities research analysts predict that UroGen Pharma will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On UroGen Pharma

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock worth $103,000 after purchasing an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets increased its position in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after buying an additional 5,890 shares in the last quarter. Intech Investment Management LLC acquired a new stake in UroGen Pharma in the third quarter worth about $155,000. Verition Fund Management LLC purchased a new stake in shares of UroGen Pharma during the third quarter worth about $168,000. Finally, SG Americas Securities LLC purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at approximately $179,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.